Prostaglandins and ischemic heart disease. Am J Med 1981 Dec;71(6):1009-26
Date
12/01/1981Pubmed ID
7032286DOI
10.1016/0002-9343(81)90335-1Scopus ID
2-s2.0-0019814570 (requires institutional sign-in at Scopus site) 74 CitationsAbstract
There is an abundance of information suggesting that prostaglandins are involved in the development and clinical expression of atherosclerosis. Many studies demonstrate a relationship between prostaglandins and the risk factors for peripheral and coronary artery disease. Thus, part of the mechanism by which hyperlipidemia, diabetes mellitus, smoking, hypertension, sex hormones, age, heredity, emotional stress and diet contribute to the development and progression of atherosclerosis may be through an imbalance between thromboxane A2 and prostaglandin I2. Recent studies show a temporal relationship between acute ischemic events (specifically, unstable angina) and a transcardiac increase in thromboxane B2, while others demonstrate a salutary effect of disaggregatory and vasodilatory prostaglandins in such patients. If prostaglandins and thromboxane prove important in ischemic vascular disease, attention will be directed at the correction of their pathologic imbalance. This may be accomplished by dietary manipulation as well as by the development of prostaglandin receptor antagonists or inhibitors of specific prostaglandin pathways.
Author List
Hirsh PD, Campbell WB, Willerson JT, Hillis LDAuthor
William B. Campbell PhD Professor in the Pharmacology and Toxicology department at Medical College of WisconsinMESH terms used to index this publication - Major topics in bold
Age FactorsArteriosclerosis
Coronary Disease
Diabetes Mellitus
Diet
Epoprostenol
Gonadal Steroid Hormones
Humans
Hyperlipidemias
Hypertension
Prostaglandin Antagonists
Prostaglandins
Receptors, Prostaglandin
Risk
Smoking
Stress, Physiological
Thromboxane A2
Thromboxane B2
